Reduced‐dose chemotherapy followed by blinatumomab in induction therapy for newly diagnosed B‐cell acute lymphoblastic leukemia

Abstract Background Blinatumomab early‐line treatment in B‐cell precursor acute lymphoblastic leukemia (B‐ALL) might improve clinical outcomes. Methods We conducted a retrospective real‐world cohort analysis in 20 newly diagnosed B‐ALL patients who received reduced‐dose chemotherapy (idarubicin, vindesine, and dexamethasone) for 1–3 weeks, followed by blinatumomab for 1–4 weeks as an induction therapy. Results At the end of the induction therapy, a complete remission rate of 100% was achieved; 17 (85%) patients were minimal residual disease (MRD) negative (